MedTrace Logo

Influenza Vaccine Elicited Immune Response in Immunocompromised Patients

NCT06738082 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 147

Last updated 2025-03-26

No results posted yet for this study

Summary

This study aims to understand how well influenza vaccines work in some individuals with weakened immune systems compared to healthy individuals. Some people, such as those with HIV, multiple sclerosis, certain cancers, or autoimmune conditions, have more severe influenza disease courses due to their medical treatments. These individuals may also respond less effectively to vaccines. By comparing immune responses to the influenza vaccine in both immunocompromised patients and healthy participants, this study aims to identify patterns in vaccine effectiveness and side effects. The goal is to find better ways to predict vaccine response in vulnerable patients and improve protection against influenza.

Conditions

Interventions

BIOLOGICAL

Influenza vaccine

Standard, commercially available, quadrivalent split-vaccine against influenza is given to all study participants.

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Christine Thurnheer, PD, MD · University Hospital Bern, Switzerland

  • Cédric Hirzel, PD, MD · University Hospital Bern, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-15
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06738082 on ClinicalTrials.gov